Cost–effectiveness of standard utilization of zoledronic acid for bone metastases from advanced lung cancer in China. (29th March 2019)

• Record Type: Journal Article
• Authors: Yu, Zhanwu; Liu, Yu; Cui, Ying; Ma, Rui; Zhan, Huan; Chen, Wendong; Liu, Hongxu
• Is Part Of: Journal of comparative effectiveness research. Volume 8:Number 7(2019)
• Page Start: 487
• Page End: 495
• Publication Date: 2019-03-29
• Subjects: bone metastasis -- cost–effectiveness -- lung cancer -- skeletal-related events -- zoledronic acid; Medical care -- Research -- Periodicals; Medical care -- Research -- Evaluation -- Periodicals; Medical care -- Decision making -- Periodicals; Evidence-based medicine -- Periodicals; Medicine, Comparative -- Periodicals; 362.1072
• DOI: 10.2217/cer-2018-0127
• Languages: English
• ISSNs: 2042-6305

Abstract

Aim: To assess the cost–effectiveness of standard utilization of zoledronic acid (ZA) relative to real-world utilization of ZA for bone metastasis (BM) in Chinese patients with advanced lung cancer.Materials & methods: A decision analytic model was constructed to simulate health benefits and medical costs associated with standard and real-world utilization of ZA for BM in Chinese patients with advanced lung cancer.Results: Compared with real-world utilization of ZA, standard utilization of ZA reduced cumulative risk of skeletal-related events (45.7 vs 63.6%), increased quality-adjusted life years (0.673 vs 0.626 QALY) and saved cumulated medical costs (¥343, 163 vs ¥376, 943).Conclusion: Standard utilization of ZA dominated real-world utilization of ZA for BM in Chinese patients with advanced lung cancer from cost–effectiveness perspective.